Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Fujirebio Diagnostics, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to evaluate the significance of KL-6 as a biomarker in the clinical diagnosis of interstitial lung disease (ILD) by detecting serum KL-6 levels among patients with ILD, and comparing them to the clinical diagnostic criteria and other respiratory diseases. In addition, the study discusses the value of KL-6 levels in terms of ILD treatment effect evaluation through the detection of serum KL-6 levels before treatment and after treatment.
As a multi-center, double-blind clinical study, the trial is divided into two parts.
Part 1: The purpose of this part is to evaluate the role of KL-6 as a biomarker in the clinical diagnosis of interstitial lung disease (ILD) by detecting serum KL-6 levels among patients with ILD, and comparing them to the clinical diagnostic criteria and other respiratory diseases, including pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease and healthy control group.
Part 2: The purpose of this part is to study the value of KL-6 levels in terms of ILD treatment effect evaluation through the detection of serum KL-6 levels before treatment and 30-90 days after treatment. Treatment includes anti fibrosis, anti-inflammatory and other conventional therapies.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ILD, Other respiratory diseases, Healthy control group | ILD: those with interstitial lung disease. Other respiratory diseases: those with other respiratory disease including pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease. Healthy control group: those who is healthy. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| The KL-6 concentration on the immune analyzer | Detect the KL-6 concentration in serum by the use of the immune analyzer among patients with ILD. | The serum from patients with ILD will be collected for the duration of hospital stay, an average of 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| The KL-6 concentration on the immune analyzer | Detect the KL-6 concentration in serum by the use of the immune analyzer among patients with other respiratory diseases, including pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease. | The serum from patients other respiratory diseases will be collected for the duration of hospital stay, an average of 4 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
The serums from clinical laboratory of Shanghai Pulmonary Hospital, Nanjing Drum Tower Hospital and Beijing Chaoyang Hospital.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Li Hui Ping | Shanghai Pulmonary Hospital , Tongji University | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D017563 | Lung Diseases, Interstitial |
| D004194 | Disease |
| C536137 | Medullary cystic kidney disease 1 |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
The residual serums in the clinical laboratory.
| The KL-6 concentration on the immune analyzer | Detect the KL-6 concentration in serum by the use of the immune analyzer among healthy people. | The serum from healthy people will be collected for the duration of physical examination, an average of 1 day |
| Change of KL-6 concentration on the immune analyzer | Change of KL-6 concentration on the immune analyzer from pretherapy to 30-90 days after treatment among patients with ILD. | pretherapy, 30-90 days after treatment |